Recent clinical trial results have revealed that Car T-cell therapy, an innovative immunotherapy, extends the life of patients with advanced gastric or gastro-oesophageal junction cancers by approximately 40% compared to traditional treatments. This therapy involves genetically modifying patients' own T-cells to target cancer cells more effectively. With solid tumors being responsible for about 90% of all cancers, these findings are pivotal, suggesting that Car T-cell therapy could revolutionize treatment not only for gastric cancers but also for various other solid tumors. The trial highlights the potential of this therapy as a lasting solution for patients who have undergone multiple previous therapies.
Patients treated with Car T-cell therapy lived on average approximately 40% longer than those receiving standard care, marking a significant advancement in cancer treatment.
The study represents a groundbreaking milestone for Car T-cells against solid tumors, potentially transforming treatment for advanced gastric or gastro-oesophageal cancer.
Collection
[
|
...
]